地特胰岛素与其他基础胰岛素在孕前糖尿病孕妇中的严重不良妊娠结局风险:EVOLVE真实世界研究
EVOLVE研究为多国前瞻性队列,纳入1457例孕前糖尿病孕妇,比较地特胰岛素与其他基础胰岛素对新生儿无严重先天畸形或围产期/新生儿死亡(主要终点)的影响。结果显示两组主要终点患病率相似(97.0% vs 95.5%),校正后风险差异无统计学意义;地特胰岛素组粗数据中母体HbA1c、严重低血糖、子痫前期和死产率较低,但校正后差异不显著。
要点
- 地特胰岛素与其他基础胰岛素的主要终点风险相似,校正后无显著差异。
- 粗数据中地特胰岛素组先天畸形、低血糖、子痫前期和死产率较低,但校正后不显著。
- 孕前糖尿病孕妇使用地特胰岛素未增加严重不良妊娠结局风险。
核心结论
- 地特胰岛素与其他基础胰岛素相比,主要先天畸形、围产期或新生儿死亡、低血糖、子痫前期和死产风险相似。
研究设计与样本
- 多国前瞻性队列研究,纳入1457例孕前糖尿病孕妇,其中727例接受地特胰岛素,730例接受其他基础胰岛素。
主要发现
- 新生儿无主要先天畸形或围产期/新生儿死亡的患病率:地特胰岛素97.0%,其他基础胰岛素95.5%(粗风险差异0.015 [95%CI -0.01, 0.04];校正风险差异-0.003 [95%CI -0.03, 0.03])。
- 至少一种先天畸形(主要加次要)的粗患病率:地特胰岛素9.4% vs 其他基础胰岛素12.6%,校正前风险差异-0.032 [95%CI -0.064, 0.000],校正后-0.036 [95%CI -0.081, 0.009]。
- 粗数据显示地特胰岛素组孕早期HbA1c较低(6.5% vs 6.7% [48 vs 50 mmol/mol];估计平均差异-0.181 [95%CI -0.300, -0.062]),孕中期也较低(6.1% vs 6.3% [43 vs 45 mmol/mol];-0.139 [95%CI -0.232, -0.046])。
- 粗数据显示地特胰岛素组严重低血糖(6.0% vs 9.0%;风险差异-0.030 [95%CI -0.058, -0.002])、子痫前期(6.4% vs 10.0%;-0.036 [95%CI -0.064, -0.007])和死产(0.4% vs 1.8%;-0.013 [95%CI -0.024, -0.002])患病率较低。
- 上述差异在校正混杂因素后均不显著。
临床怎么用
- 孕前糖尿病孕妇使用地特胰岛素与其他基础胰岛素的严重不良妊娠结局风险相似,可作为基础胰岛素选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of severe adverse pregnancy complications in women with preexisting diabetes. RESEARCH DESIGN AND METHODS: Multinational, prospective cohort study to assess the prevalence of newborns free from major congenital malformations or perinatal or neonatal death (primary end point) following treatment with insulin detemir (detemir) versus other basal insulins. RESULTS: Of 1,457 women included, 727 received detemir and 730 received other basal insulins. The prevalence of newborns free from major congenital malformations or perinatal or neonatal death was similar between detemir (97.0%) and other basal insulins (95.5%) (crude risk difference 0.015 [95% CI -0.01, 0.04]; adjusted risk difference -0.003 [95% CI -0.03, 0.03]). The crude prevalence of one or more congenital malformations (major plus minor) was 9.4% vs. 12.6%, with a similar risk difference before (-0.032 [95% CI -0.064, 0.000]) and after (-0.036 [95% CI -0.081, 0.009]) adjustment for confounders. Crude data showed lower maternal HbA1c during the first trimester (6.5% vs. 6.7% [48 vs. 50 mmol/mol]; estimated mean difference -0.181 [95% CI -0.300, -0.062]) and the second trimester (6.1% vs. 6.3% [43 vs. 45 mmol/mol]; -0.139 [95% CI -0.232, -0.046]) and a lower prevalence of major hypoglycemia (6.0% vs. 9.0%; risk difference -0.030 [95% CI -0.058, -0.002]), preeclampsia (6.4% vs. 10.0%; -0.036 [95% CI -0.064, -0.007]), and stillbirth (0.4% vs. 1.8%; -0.013 [95% CI -0.024, -0.002]) with detemir compared with other basal insulins. However, differences were not significant postadjustment. CONCLUSIONS: Insulin detemir was associated with a similar risk to other basal insulins of major congenital malformations, perinatal or neonatal death, hypoglycemia, preeclampsia, and stillbirth.
引用
- Mathiesen ER, Ali N, Alibegovic AC, et al. Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. Diabetes Care. 2021. PMID: 34330786. doi:10.2337/dc21-0472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。